ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1518

Prevalence, Risk Factors and Treatment Patterns of Digital Ischemic Complications in Systemic Sclerosis: A Single Center Cross-Sectional Study
Abstract Number: 0231

Primary Care Physician’s Perspective and Needs on Early Rheumatoid Arthritis Diagnosis: REUCARE Program for Early Referral
Abstract Number: 0222

Primary Care Provider Utilization of Musculoskeletal Ultrasound for the Diagnosis of Acute Gout Flares: A Novel Opportunity for Rheumatology-Focused Educational Curricula
Abstract Number: 2199

Primary Non-adherence to Biologics and Immunomodulatory Therapies for Rheumatoid Arthritis, Psoriatic Arthritis, and Spondyloarthritis Using Linked EHR and Pharmacy Claims Data
Abstract Number: 0727

Primary Prevention of Fractures in Osteoporotic Patients in a Southern California Academic Health System
Abstract Number: 0991

Prior Use of Autoimmune Disease Treatments Among Patients with Systemic Lupus Erythematosus, Rheumatoid Arthritis, or Myositis Hospitalized with COVID-19
Abstract Number: 1349

Priority Educational Topics to Deliver Information About Immune Checkpoint Inhibitors for Patients with Cancer and a Pre-Existing Autoimmune Disease
Abstract Number: 2247

Priority Research Topics for Vaccine Uptake Among Adults with Autoimmune Conditions
Abstract Number: 1620

Probability-based Diagnostic Algorithm in Suspected Giant Cell Arteritis: A Prospective, Multicentre Validity Data from HAS GCA Study
Abstract Number: 0235

Procedure-Based Musculoskeletal Ultrasound Curriculum for Rheumatology Fellows
Abstract Number: 1336

Productivity Analysis in Patients with Idiopathic Inflammatory Myopathies and Relationship with Quality of Life and Emotional Domain: Preliminary Data from a Monocentric Cohort
Abstract Number: 2164

Profibrotic Alveolar Macrophages as a Potential Biomarker in Systemic Sclerosis-associated Interstitial Lung Disease
Abstract Number: 0547

Profiling of Systemic Immune Responses in Axial Spondyloarthritis Patients Reveals Strikingly Distinct Cellular and Molecular Mechanisms of Action of IL-17A Inhibitors and TNF-Blockers
Abstract Number: 1605

Profound Anticoagulant Effects of Initial Antirheumatic Treatments in Early Rheumatoid Arthritis Patients; A NORD-STAR Spin-off Study
Abstract Number: 0443

Prognosis of Non-PR3 ANCA-Associated Vasculitis with Glomerulonephritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].